Fosaprepitant - Nevakar
Alternative Names: NVK-016Latest Information Update: 28 May 2022
At a glance
- Originator Nevakar
- Class Antiemetics; Fluorinated hydrocarbons; Morpholines; Phosphonic acids; Small molecules; Triazoles
- Mechanism of Action Neurokinin 1 receptor antagonists; Substance P inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chemotherapy-induced nausea and vomiting
Most Recent Events
- 28 May 2022 No recent reports of development identified for phase-I development in Chemotherapy-induced-nausea-and-vomiting(Prevention, In volunteers) in Australia (IV)
- 29 Jul 2019 Nevakar terminates a phase I trial in Chemotherapy-induced nausea and vomiting (Prevention, In volunteers) in Australia (IV) due to safety concerns (ACTRN12619000189123)
- 24 Jun 2019 Chemical structure information added